Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Carboplatin 36Cisplatin 32pembrolizumab 30Paclitaxel 29Pemetrexed 22Gemcitabine 21Nivolumab 19Dexamethasone 17Rituximab 16Fluorouracil 13Docetaxel 13durvalumab 12Ipilimumab 12Capecitabine 12Cyclophosphamide 11atezolizumab 10130-nm albumin-bound paclitaxel 10olaparib 9Trastuzumab 9Lenalidomide 9Doxorubicin 9Cytarabine 9Bevacizumab 9daratumumab 8Oxaliplatin 8Bortezomib 8Vinorelbine 7Prednisone 7Leucovorin 7venetoclax 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Has announcements × alectinib × Clear all
NCT02075840 2026-05-29

ALEX

Hoffmann-La Roche

Phase 3 Completed
303 enrolled 32 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03456076 2026-05-05

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Hoffmann-La Roche

Phase 3 Active not recruiting
257 enrolled 14 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡